Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02760329 · ClinicalTrials.gov registry record

Observational Study of Obstructive Lung Disease (NOVELTY)

A clinical trial of Asthma and Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca.

Completed
Registry status
12,255
Enrollment target
20
Study locations

NCT02760329 is a study of Asthma and Chronic Obstructive Pulmonary Disease that has completed, run by AstraZeneca. The registered enrollment target is 12,255 participants, above the 1,531-participant average among 374 other Asthma trials with a reported enrollment target (700% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02760329, a study of Asthma and Chronic Obstructive Pulmonary Disease, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
12,255 participants
Enrollment target
20
Study locations

Study Summary

The NOVEL Observational longiTudinal studY (NOVELTY) is an observational study of obstructive lung disease and is a multi-country, multi-centre, prospective, longitudinal cohort study which will recruit patients with a diagnosis, or suspected diagnosis, of asthma and/or Chronic Obstructive Pulmonary Disease (COPD). Patients will undergo clinical assessments and receive standard medical care as determined by their treating physician. Patients enrolled in NOVELTY will be followed up yearly by their treating physician for a total duration of three years. In addition, patients will be followed up remotely every 3 months. The NOVELTY study will collect data currently lacking to allow for multinational data collection to fill regional/local gaps and improve comparability across regions.

Conditions Studied

Asthma Chronic Obstructive Pulmonary Disease COPD

Interventions

  • PROCEDURE Blood draw
  • PROCEDURE Urine
  • PROCEDURE Lung function measurements
  • PROCEDURE Fractional Exhaled Nitric Oxide (FENO)

Study Locations (20)

Florida

  • Research Site - Clearwater
  • Research Site - Gainesville
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Plantation

California

  • Research Site - Loma Linda
  • Research Site - Long Beach
  • Research Site - Roseville

Michigan

  • Research Site - Ann Arbor
  • Research Site - Buckley
  • Research Site - Hamtramck

Colorado

  • Research Site - Aurora
  • Research Site - Colorado Springs

Illinois

  • Research Site - Chicago
  • Research Site - Normal

Kansas

  • Research Site - Hutchinson

Louisiana

  • Research Site - Shreveport

Massachusetts

  • Research Site - Fall River

Trial Details

FieldValue
Enrollment Target 12,255 participants
Start Date 2016-07-25
Est. Completion 2023-05-31

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02760329

The ClinicalTrials.gov registry entry for NCT02760329 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12,255 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,531-participant average among 374 other Asthma trials with a reported enrollment target (700% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Asthma appearing as the primary indexed condition, and to 4 interventions - of which Blood draw is the first listed.

NCT02760329 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT02760329 about?

NCT02760329 is a clinical study titled "Observational Study of Obstructive Lung Disease (NOVELTY)". The NOVEL Observational longiTudinal studY (NOVELTY) is an observational study of obstructive lung disease and is a multi-country, multi-centre, prospective, longitudinal cohort study which will recruit patients with a diagnosis, or suspected diagnosis, of asthma and/or Chronic Obstructive Pulmonary...

What is the current status of trial NCT02760329?

This trial is currently completed. The enrollment target is 12,255 participants. The study started on 2016-07-25. Estimated completion is 2023-05-31.

What conditions does trial NCT02760329 study?

This clinical trial studies the following conditions: Asthma, Chronic Obstructive Pulmonary Disease, COPD.

What interventions are being tested in trial NCT02760329?

The interventions under investigation include: Blood draw (PROCEDURE), Urine (PROCEDURE), Lung function measurements (PROCEDURE), Fractional Exhaled Nitric Oxide (FENO) (PROCEDURE).

Who is sponsoring clinical trial NCT02760329?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02760329 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Chronic Obstructive Pulmonary Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.